Dexamethasone reduced ACE2 upregulation and intra-alveolar markers of fibrinolysis, which, in combination with the previously shown reduced activation of coagulation, may support its beneficial role in pulmonary diseases including, but not limited to, COVID-19. This evidence concerns the gene ACE2 and COVID-19.